Oral calorie supplements for cystic fibrosis by Smyth, RL & Rayner, O
Cochrane Database of Systematic Reviews
Oral calorie supplements for cystic fibrosis (Review)
Smyth RL, Rayner O
Smyth RL, Rayner O.
Oral calorie supplements for cystic fibrosis.
Cochrane Database of Systematic Reviews 2017, Issue 5. Art. No.: CD000406.
DOI: 10.1002/14651858.CD000406.pub5.
www.cochranelibrary.com
Oral calorie supplements for cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
8BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
15REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
18CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Analysis 1.1. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional advice, Outcome 1
Change in weight (kg). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 25
Analysis 1.2. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional advice, Outcome 2
Change in weight centile (percentile points). . . . . . . . . . . . . . . . . . . . . . . . 26
Analysis 1.3. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional advice, Outcome 3
Change in height (cm). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
Analysis 1.4. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional advice, Outcome 4
Change in height centile (percentile points). . . . . . . . . . . . . . . . . . . . . . . . 28
Analysis 1.5. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional advice, Outcome 5
Change in weight for height (percentage). . . . . . . . . . . . . . . . . . . . . . . . . 28
Analysis 1.6. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional advice, Outcome 6
Change in BMI (kg/m2). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Analysis 1.7. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional advice, Outcome 7
Change in BMI centile (percentile points). . . . . . . . . . . . . . . . . . . . . . . . . 30
Analysis 1.8. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional advice, Outcome 8
Change in mid-upper arm circumference (cm). . . . . . . . . . . . . . . . . . . . . . . 31
Analysis 1.9. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional advice, Outcome 9
Change in total Kcal/day. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 32
Analysis 1.10. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional advice, Outcome 10
Change in total protein (g)/day. . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
Analysis 1.11. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional advice, Outcome 11
Change in total fat (g)/day. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 34
Analysis 1.12. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional advice, Outcome 12
Change in FEV (% predicted). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Analysis 1.13. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional advice, Outcome 13
Change in FVC (% predicted). . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
Analysis 1.14. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional advice, Outcome 14
Change in activity (% 24 hours). . . . . . . . . . . . . . . . . . . . . . . . . . . . 37
37WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
37HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
39CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
39DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
40SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
40DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
40NOTES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
40INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iOral calorie supplements for cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Oral calorie supplements for cystic fibrosis
Rosalind L Smyth1, Oli Rayner2
1Institute of Child Health, UCL, London, UK. 2CF Trust, Bromley, UK
Contact address: Rosalind L Smyth, Institute of Child Health, UCL, 30 Guilford Street, London, WC1N 1EH, UK.
rosalind.smyth@ucl.ac.uk.
Editorial group: Cochrane Cystic Fibrosis and Genetic Disorders Group.
Publication status and date: New search for studies and content updated (no change to conclusions), published in Issue 5, 2017.
Citation: Smyth RL, Rayner O. Oral calorie supplements for cystic fibrosis. Cochrane Database of Systematic Reviews 2017, Issue 5.
Art. No.: CD000406. DOI: 10.1002/14651858.CD000406.pub5.
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
Poor nutrition occurs frequently in people with cystic fibrosis and is associated with other adverse outcomes. Oral calorie supplements
are used to increase total daily calorie intake and improve weight gain. However, they are expensive and there are concerns they may
reduce the amount of food eaten and not improve overall energy intake. This is an update of a previously published review.
Objectives
To establish whether in people with cystic fibrosis, oral calorie supplements: increase daily calorie intake; and improve overall nutritional
intake, nutritional indices, lung function, survival and quality of life. To assess adverse effects associated with using these supplements.
Search methods
We searched the Cochrane Cystic Fibrosis Trials Register comprising references from comprehensive electronic database searches,
handsearches of relevant journals and abstract books of conference proceedings. We contacted companies marketing oral calorie
supplements.
Last search: 18 October 2016.
Selection criteria
Randomised or quasi-randomised controlled trials comparing use of oral calorie supplements for at least one month to increase calorie
intake with no specific intervention or additional nutritional advice in people with cystic fibrosis.
Data collection and analysis
We independently selected the included trials, assessed risk of bias and extracted data. We contacted the authors of included trials and
obtained additional information for two trials.
Main results
We identified 21 trials and included three, reporting results from 131 participants lasting between three months and one year. Two
trials compared supplements to additional nutritional advice and one to no intervention. Two of the included trials recruited only
children. In one trial the risk of bias was low across all domains, in a second trial the risk of bias was largely unclear and in the third
mainly low. Blinding of participants was unclear in two of the trials. Also, in one trial the clinical condition of groups appeared to be
unevenly balanced at baseline and in another trial there were concerns surrounding allocation concealment. There were no significant
differences between people receiving supplements or dietary advice alone for change in weight, height, body mass index, z score or
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other indices of nutrition or growth. Changes in weight (kg) at three, six and 12 months respectively were: mean difference (MD) 0.32
(95% confidence interval (CI) -0.09 to 0.72); MD 0.47 (95% CI -0.07 to 1.02 ); and MD 0.16 (-0.68 to 1.00). Total calorie intake
was greater in people taking supplements at 12 months, MD 265.70 (95% CI 42.94 to 488.46). There were no significant differences
between the groups for anthropometric measures of body composition, lung function, gastro-intestinal adverse effects or activity levels.
Moderate quality evidence exists for the outcomes of changes in weight and height and low quality evidence exists for the outcomes of
change in total calories, total fat and total protein intake as results are applicable only to children between the ages of 2 and 15 years
and many post-treatment diet diaries were not returned. Evidence for the rate of adverse events in the treatment groups was extremely
limited and judged to be of very low quality
Authors’ conclusions
Oral calorie supplements do not confer any additional benefit in the nutritional management of moderately malnourished children
with cystic fibrosis over and above the use of dietary advice and monitoring alone. While nutritional supplements may be used, they
should not be regarded as essential. Further randomised controlled trials are needed to establish the role of short-term oral protein
energy supplements in people with cystic fibrosis and acute weight loss and also for the long-term nutritional management of adults
with cystic fibrosis or advanced lung disease, or both.
P L A I N L A N G U A G E S U M M A R Y
Use of oral supplements to increase calorie intake in people with cystic fibrosis
We reviewed the evidence for the use of oral supplements to increase calorie intake in people with cystic fibrosis.
Background
Cystic fibrosis affects many organs, including the digestive system, and can lead to food not being absorbed as it should be, which in turn
leads to growth problems. Children with cystic fibrosis need more energy than other children, but they often have reduced appetites.
Poor diet has been linked to poor outcomes in cystic fibrosis. Milks or juices containing additional calories are often added to the diets
of children with cystic fibrosis to increase their total daily calorie intake and help them gain weight. However, these supplements are
expensive and may not achieve the desired effect if patients take them as a substitute for calories consumed from food rather than as an
additional component. In toddlers or young children use of supplements may risk compromising the development of normal eating
behaviour. This is an updated version of the review.
Search date
We last searched for evidence on 18 October 2016.
Study characteristics
This review includes three randomised controlled trials with a total of 131 participants and two of them only included children. Two of
the trials compared supplements to dietary advice and one compared supplements to no advice. The trials lasted between three months
and one year.
Key results
Therewere nomajor differences betweenpeople receiving supplements or just dietary advice for any nutritional or growthmeasurements.
This was also true for measures of body composition, lung function, adverse effects on the digestive system or people’s levels of activity.
Advice and monitoring appear to be enough to manage the diet of moderately malnourished children.
Future trials should look into the use of calorie supplements for acute weight loss or long-term care for adults with cystic fibrosis.
Quality of the evidence
One of the trials appeared to be well run and the risk of bias was low for all the aspects of trial design that we assessed; so we do not
think any bias will influence the results in a negative way. In the other two trials, we were not sure if the people taking part could guess
which treatment group they were in. In one of these two trials, we further thought it was likely that the person recruiting them to
the trial knew which group the participant would be in. In the second of these trials, the people in the group receiving supplements
appeared to be generally in better clinical condition at the start of the trial than those who didn’t receive any supplements or advice.
These factors affect our confidence in the results from these trials.
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We judged the quality of the evidence for the changes in weight and height to be moderate, but judged the quality of the evidence for
the changes in total calories, total fat and total protein intake as low since results are applicable only to children aged between 2 and
15 years; also many post-treatment diet diaries were not returned to the investigators. Evidence for the rate of adverse events in the
treatment groups was extremely limited and judged to be of very low quality.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Oral calorie supplements compared with control for cystic fibrosis
Patient or population: adults and children with cyst ic f ibrosis
Settings: outpat ients
Intervention: oral calorie supplements
Comparison: control (no intervent ion, dietary advice or nutrit ional counselling)
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Control (no interven-
tion, dietary advice
or nutritional coun-
selling)
Oral calorie supple-
ments
Change in weight (kg):
1 at 12 months
Follow-up: up to 12
months
The mean change in
weight was 2.97 kg
gained in the control
group
The mean change in
weight was 0.16 kg ex-
tra gained (0.68 kg lost
to 1.00 kg extra gained)
in the treatment group
NA 102
(1 trial)
⊕⊕⊕©
moderate2
There was also no sig-
nif icant dif f erence be-
tween treatment
groups at 3 months (MD
0.32 kg, 95% CI -0.09
kg to 0.72 kg, 112 par-
t icipants, 2 trials) or at
6 months (MD 0.47 kg,
95% CI -0.07 kg to 1.02
kg, 117 part icipants, 2
trials)
There was also no sig-
nif icant dif f erence in
change in weight cen-
t ile between treatment
groups at 3, 6 and 12
months
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Change in height (cm):
1
at 12 months
Follow-up: up to 12
months
The mean change in
height was 5.85 cm
gained in the control
group
The mean change in
height was 0.06 cm ex-
tra gained (0.50 cm
lost to 0.62 cm extra
gained) in the treatment
group
NA 102
(1 trial)
⊕⊕⊕©
moderate2
There was also no sig-
nif icant dif f erence be-
tween
treatment groups at 3
months (MD -0.04 cm,
95% CI -0.36 cm to 0.29
cm, 112 part icipants, 2
trials) or at 6 months
(MD -0.47 cm, 95% CI -
1.32 cm to 0.38 cm, 101
part icipants, 1 trial)
There was also no sig-
nif icant dif f erence in
change in height cen-
t ile between treatment
groups at 3, 6 and 12
months
Change in total calories
(Kcal/ day):
at 12 months
Follow-up: up to 12
months
The mean change in to-
tal calories was 139.52
Kcal/ day in the control
group
The mean change in to-
tal calories was 265.
70 Kcal/ day higher (42.
94 to 488.46 Kcal/ day
higher) in the treatment
group
NA 58
(1 trial)
⊕⊕©©
low2,3
There was also a signif -
icant advantage to the
treatment group over
the control group at
6 months (MD 304.
86 Kcal/ day, 95% CI
5.62 kcal/ day to 604.
10 Kcal/ day, 48 part ici-
pants, 1 trial)
There was no sig-
nif icant dif f erence be-
tween treatment
groups at 3 months
(MD 115.09 Kcal/ day,
95% CI -121.34 Kcal/
day to 351.52 Kcal/ day,
58 part icipants, 2 trials)
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Change in total protein
(g/ day):
at 12 months
Follow-up: up to 12
months
The mean change in to-
tal protein was 5.75 g/
day in the control group
The mean change in to-
tal calories was 6.82 g/
day higher (2.36 g/ day
lower to 16.00 g/ day
higher) in the treatment
group
NA 58
(1 trial)
⊕⊕©©
low2,3
There was also no sig-
nif icant dif f erence be-
tween treatment
groups at 3 months (MD
2.51 g/ day, 95% CI -6.
74 g/ day to 11.77 g/
day, 58 part icipants, 2
trials) or at 6 months
(MD 8.77 g/ day, 95% CI
-1.24 g/ day to 18.78 g/
day, 48 part icipants, 1
trial)
Change in total fat (g/
day):
at 12 months
Follow up: up to 12
months
The mean change in to-
tal fat was 12.23 g/ day
in the control group
The mean change in to-
tal calories was 8.85 g/
day higher (4.64 g/ day
lower to 22.34 g/ day
higher) in the treatment
group
NA 58
(1 trial)
⊕⊕©©
low2,3
There was also no sig-
nif icant dif f erence be-
tween treatment
groups at 3 months (MD
-1.10 g/ day, 95% CI -15.
05 g/ day to 12.85 g/
day, 58 part icipants, 2
trials) or at 6 months
(MD 11.74 g/ day, 95%
CI -2.96 g/ day to 26.44
g/ day, 48 part icipants,
1 trial)
Adverse events:
Follow up: up to 12
months
See comment See comment NA Not stated
(1 trial)
⊕©©©
very low4
One trial invest igated
gastro-intest inal symp-
toms with a quest ion-
naire and reported no
signif icant dif f erence
between the groups
Change in lung func-
tion - FEV (% pre-
dicted):
at 12 months
The mean change in
FEV (%predicted) was
-1.5 in the control group
The mean change in
FEV (% predicted) 1.
91 lower (8.57 lower to
4.75 higher) in the treat-
NA 70
(1 trial)
⊕⊕©©
low2,5
There was a signif i-
cant decline in FEV
(% predicted) in the
treatment group com-
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Follow-up: up to 12
months
ment group pared to the control
group at 3 months
(MD -7.96, 95% CI -
13.52 to -2.40). There
was no signif icant dif -
ference between treat-
ment groups at 6
months (MD -3.39, 95%
CI -9.97 to 3.19)
There was also no sig-
nif icant dif f erence in
change in FVC between
treatment groups at 3,
6 and 12 months
* The basis for the assumed risk is the mean control group risk across studies. The corresponding risk (and its 95% conf idence interval) is based on the assumed risk in the
comparison group and the relative effect of the intervent ion (and its 95% CI).
BM I: body mass index; CI: conf idence interval; FEV : f orced expiratory volume at 1 second; FVC: f orced vital capacity; M D: mean dif ference; NA: not applicable
GRADE Working Group grades of evidence
High quality: f urther research is very unlikely to change our conf idence in the est imate of ef fect.
M oderate quality: f urther research is likely to have an important impact on our conf idence in the est imate of ef fect and may change the est imate.
Low quality: f urther research is very likely to have an important impact on our conf idence in the est imate of ef fect and is likely to change the est imate.
Very low quality: we are very uncertain about the est imate.
1. There was also no signif icant dif f erence in terms of other indices of nutrit ion or growth; weight for height (percentage) at 3
months, change in BMI (kg/ m²) at 3, 6 and 12 months and change in BMI cent ile at 3 and 12 months. There was a signif icant
advantage for oral calorie supplements over control at 6 months (MD 5.75, 95% CI 0.22 to 11.28, 101 part icipants, 1 trial).
2. Downgraded once due to applicability; results apply only to children between the ages of 2 and 15 years, results not
applicable to adults.
3. Downgraded once due to incomplete outcome data; 58 out of 102 children returned the 12 month dietary diary, 44 who did
not return the diary are excluded f rom analysis.
4. Downgraded twice due to imprecision and once due to risk of select ive outcome report ing bias; adverse events of treatment
were reported in only a single trial and very lim ited information was provided about the rate of adverse events.
5. Downgraded once due to applicability; Spirometry data recorded only for children over the age of 5 years, lung funct ion
outcomes are not applicable to children between the ages of 2 to 5 years f rom this study.
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B A C K G R O U N D
Description of the condition
Cystic fibrosis (CF) is a multisystem disorder affecting many or-
gans including the lungs, gastro-intestinal tract, pancreas and liver.
Failure to thrive is a common means of presentation of undiag-
nosed children with CF; and poor nutrition may be a problem
in the children and adults diagnosed with CF (Shepherd 1980).
This may worsen as the disease progresses. In recent years guide-
lines have recommended that dietary intake should provide at least
120% of the recommended daily allowance for energy in people
with cystic fibrosis (Sinaasappel 2002). This increased calorie re-
quirement is contributed to by multiple factors. These include
malabsorption and, in children or adults withmore advanced chest
disease, it may also be contributed to by increased work of breath-
ing or chronic pulmonary sepsis. In addition, when unwell, people
with CF may have reduced appetite. It was suggested by studies in
the 1980s that there was an increased energy requirement associ-
ated with the basic defect of CF (Shepherd 1988), but this is now
disputed and resting energy expenditure in clinical stable children
with CF has been shown to be similar to control children without
CF (Marin 2004). Poor nutrition has been associated with ad-
verse outcomes in CF and therefore nutritional management is di-
rected at maintaining normal weight and height for age in people
with CF (MacDonald 1996). There is a further systematic review
which assesses the effectiveness of this intervention for children
with chronic disease (Francis 2015).
Description of the intervention
Oral calorie supplements (OCS) are usually in the form of either
fortified milk or juice drinks or simple energy sources.
How the intervention might work
These supplements are used to try and increase the total daily
calorie intake and thereby improve weight gain. Provided calorie
supplements are taken in addition to normal dietary intake from
food, then overall calorie intake should be improved.
Why it is important to do this review
However, it is possible that OCS may replace some of the calories
taken as food and their potential effect on overall total calorie in-
take be either reduced or eliminated. A further potential adverse
consequence of replacing calorie intake from normal food by calo-
ries from OCS may be to have a detrimental effect on normal eat-
ing behaviour, which is particularly critical in toddlers and young
children who are learning to develop normal eating behaviour. In
addition, OCS are expensive and therefore it is important to eval-
uate their effectiveness. The cost for a 10-year old child is about
£1124 per annum in the UK (RLCH 2006).
This is an updated version of previously published reviews (Smyth
2000; Smyth 2007; Smyth 2012; Smyth 2014).
O B J E C T I V E S
To examine the evidence that in people with CF oral calorie sup-
plements:
• improve measures of nutritional status, lung function and
survival and quality of life;
• increase daily calorie intake, without reducing calorie intake
from normal food;
• are associated with adverse effects in people with CF, which
are either important to the individual or have long-term sequelae.
These may include diarrhoea, reduced appetite, and bloating.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs), published or unpublished.
Trials, where quasi-randomisation methods such as alternation are
used, would be included if there was sufficient evidence that the
treatment and comparison groups were comparable in terms of
clinical and nutritional status.
Types of participants
Children and adults with defined CF, diagnosed clinically and
by sweat or genetic testing, including all ages and all degrees of
severity, including severity of undernutrition.
Types of interventions
Oral calorie supplements, in the form of either fortified milk or
juice drinks or as simple energy sources, given in any amount for a
period of at least one month, where these have been compared to
existing conventional therapies in people with CF. Existing con-
ventional therapies may include nutritional advice on how to im-
prove calorie input from food or no specific intervention. These
two control groups will be analysed separately when there are suf-
ficient studies available. Trials where OCS are used for reasons
other than to increase calorie intake were excluded.
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Types of outcome measures
Primary outcomes
1. Change in weight or height or body mass index (BMI) or z
score or other indices of nutrition or growth
Secondary outcomes
1. Anthropometric measures of body composition
2. Total calorie intake measured daily or weekly or over some
other time interval
3. Calorie intake from food measured daily, weekly or over
some other time interval
4. Calorie intake from OCS measured daily, weekly or over
some other time interval
5. Nutrient intake measured daily, weekly or at some other
time interval
6. Measures of eating behaviour
7. Measures of quality of life
8. Adverse effects including diarrhoea, reduced appetite,
abdominal bloating, episodes of distal intestinal obstruction
syndrome and any other adverse effects reported
9. Measures of lung function
10. Number of deaths or age at death in each group
11. Activity levels (post hoc change)
Search methods for identification of studies
There will be no restrictions regarding language or publication
status.
Electronic searches
Relevant trials were identified from the Group’s Cystic Fibrosis
Trials Register using the terms: calorie supplements AND oral.
The Cystic Fibrosis Trials Register is compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTAL) (updated each new issue of theCochrane Library),
weekly searches ofMEDLINE, a search of Embase to 1995 and the
prospective handsearching of two journals - Pediatric Pulmonology
and theJournal of Cystic Fibrosis. Unpublished work is identified
by searching the abstract books of three major cystic fibrosis con-
ferences: the International Cystic Fibrosis Conference; the Euro-
pean Cystic Fibrosis Conference and the North American Cystic
Fibrosis Conference. For full details of all searching activities for
the register, please see the relevant sections of the Cystic Fibrosis
and Genetic Disorders Group Module.
Date of the most recent search of the Group’s CF Trials Register:
18 October 2016.
Searching other resources
In addition, full text searching of theJournal of Pediatrics from
1988 to 1996 was undertaken. Additional RCTs were found from
the reference lists provided by the review group. Furthermore,
the companies which manufacture OCS were contacted to ask
whether they have data on RCTs of OCS in CF on file.
Data collection and analysis
Selection of studies
The two authors independently selected the trials to be included
in the review. Any disagreements were resolved by discussion.
Data extraction and management
Each author independently extracted data and again any disagree-
ments were resolved by discussion.
Outcome data were grouped into those measured at one, three, six,
12 months and annually thereafter. If outcome data were recorded
at other time periods then consideration was given to examining
these as well.
Assessment of risk of bias in included studies
In order to establish a risk of bias for each included trial, each
author assessed the methodological quality of each trial. In par-
ticular, authors examined details of generation of the randomisa-
tion sequence and allocation concealment. If these were consid-
ered adequate the authors deemed the trial to be at low risk of
bias. The authors also assessed whether the trial was blinded. The
more people blinded to an intervention (participants, clinicians
and outcome assessors), the lower the risk of bias would be for
that trial. The authors also examined whether intention-to-treat
analyses were possible from the available data and if the number of
participants lost to follow up or subsequently excluded from the
trial was recorded. Any trials which did not discuss or account for
missing data or participants was thought to have a potential risk
of bias. For quasi-randomised studies, each author examined the
baseline characteristics of the intervention and comparison groups
to assess whether the two groups were comparable. If groups were
not comparable, there would be a risk of bias.
Measures of treatment effect
For binary outcome measures, we aimed to calculate a pooled
estimate of the treatment effect for each outcome across trials (the
odds of an outcome among treatment allocated participants to the
corresponding odds among controls). For continuous outcomes,
we recorded either mean change from baseline for each group or
mean post-treatment/intervention values and standard deviation
or standard error for each group. We aimed to calculate a pooled
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estimate of treatment effect by determining the mean difference
(MD) and corresponding 95% confidence intervals (CIs).
Unit of analysis issues
We do not plan to include any cross-over trials as this design is not
appropriate to assess the effect of the intervention or the above-
mentioned outcomes.
Dealing with missing data
In order to allow an intention-to-treat analysis, we sought data on
the number of participants with each outcome event, by allocated
treated group, irrespective of compliance and whether or not the
participant was later thought to be ineligible or otherwise excluded
from treatment or follow up.
Where data were not available in the published trial reports, we
contacted the lead investigator of the trial for further information.
Assessment of heterogeneity
We planned that heterogeneity between trial results would be
tested for using a standard Chi² test.
Data synthesis
We analysed the data using a fixed-effect model. We had originally
planned to analyse data using a random-effects model if we had
identified significant heterogeneity between trials.
Subgroup analysis and investigation of heterogeneity
We originally planned to perform subgroup analyses stratified ac-
cording to type of control group(s) used, age and severity of nu-
tritional status.
Sensitivity analysis
We also planned to perform a sensitivity analysis based on the
methodological quality of the trials, including and excluding
quasi-randomised trials.
Summary of findings and quality of the evidence
(GRADE)
In a post hoc change from protocol, we have presented a summary
of findings tables for the comparison of oral calorie supplements
compared to control (no intervention, dietary advice or nutritional
counselling) for adults and childrenwithCF (Summary of findings
for the main comparison)
The following outcomes were reported in the tables (chosen based
on relevance to clinicians and consumers): change in weight (kg),
change in height (cm), change in total calories (kcal/day), change
in total protein (g/day), change in total fat (g/day), adverse events,
lung function (change in per cent (%) predicted FEV ). All out-
comes are reported at 12 months.
We determined the quality of the evidence using the GRADE
approach; and downgraded evidence in the presence of a high
risk of bias in at least one study, indirectness of the evidence,
unexplained heterogeneity or inconsistency, imprecision of results,
high probability of publication bias. We downgraded evidence by
one level if they considered the limitation to be serious and by two
levels if very serious.
R E S U L T S
Description of studies
Results of the search
The searches for this review identified a total of 22 potentially eli-
gible trials. Three trials were included in the review; 18 trials were
excluded from the review; and one trial is awaiting classification.
Included studies
All three included trials (n = 131) have been published as abstracts
and full papers (Hanning 1993; Kalnins 2005; Poustie 2006).
Trial design
Two trials were RCTs (Hanning 1993; Poustie 2006) and one
was a quasi-RCT (Kalnins 2005). All three were of parallel design
(Hanning 1993; Kalnins 2005; Poustie 2006). Two trials were sin-
gle centre (Hanning 1993; Kalnins 2005) and one was multicen-
tre with included participants recruited from 17 hospitals (Poustie
2006). All three trials had differing durations: in one the inter-
vention was given for three months with a total of six months
follow-up (Kalnins 2005); in the second trial the intervention was
given for six months (Hanning 1993); and in the third trial, the
intervention was given for 12 months (Poustie 2006).
One trial was an explanatory trial (Hanning 1993) (an explana-
tory trial is one which looks at biological mechanisms, rather than
one which aims to provide sound treatment recommendations
(Murray 1991)). Themain aimof this trial was to investigate the re-
lationship between nutritional status and skeletal muscle strength.
Since they are investigating the biological effects of treatment, ex-
planatory trials usually only analyse the information on individu-
als who completed treatment, which was the case in this trial. Two
trials presented data using an ITT analysis (Kalnins 2005; Poustie
2006).
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Participants
Numbers of participants ranged from 15 (Kalnins 2005) to 102
(Poustie 2006). Two trials enrolled children up to 15 years of age (
Hanning 1993; Poustie 2006) and one trial included both children
and adults (Kalnins 2005). In two studies there were almost equal
numbers of males and females (Hanning 1993; Poustie 2006), but
in one trial there were more females (n = 10) than males (n = 3)
(Kalnins 2005).
All trials supplied details of participant characteristics at baseline
(Hanning 1993; Kalnins 2005; Poustie 2006). In the Hanning
trial, although the participants were described as having mild to
moderate lung disease and were randomised with adequate allo-
cation concealment, the treatment and control groups were not
similar at baseline; the treatment group appearing to be in better
clinical condition (Hanning 1993).
Two trials stated inclusion criteria: for the Kalnins trial these were
below 90% ideal weight for height or a 5% reduction in ideal
weight for height over three months (Kalnins 2005); and in the
CALICO trial at least one of the following - a BMI below the 25th
centile but over 0.4th centile, or no increase in weight over the
previous three months, or a 5% decrease in weight from baseline
over a period shorter than six months (Poustie 2006).
Interventions
The interventions in the included trials were targeted to achieve
an increase in energy intake of 20% (Kalnins 2005; Poustie 2006)
or 25% (Hanning 1993). Two trials compared dietary advice in
addition to supplements in the form of drinks to dietary advice
alone (Kalnins 2005; Poustie 2006). One trial compared the use of
dietary supplements (drink powders, milk shakes or tinned pud-
dings) to a control group receiving no additional supplements
(Hanning 1993).
Outcomes
All three trials reported on dietary energy and nutrient intake,
height, weight, anthropometric measurements and pulmonary
function (Hanning 1993; Kalnins 2005; Poustie 2006). Two trials
reported on activity levels (Hanning 1993; Poustie 2006). Han-
ning additionally reported on skeletal muscle strength and power,
respiratory muscle strength and laboratory measures of nutritional
status (e.g. albumin, amino acids) (Hanning 1993). Kalnins addi-
tionally reportedweight for height scores and faecal balance studies
(Kalnins 2005). Poustie reported BMI scores and gastro-intestinal
symptoms (Poustie 2006).
Excluded studies
A total of 18 trials were excluded for a variety of reasons. Details
can be found in the section Characteristics of excluded studies.
Seven trials did not use an oral calorie supplement in the inter-
vention (Abdulhamid 2008; Bruzzese 2007; Ellis 1998; Haworth
2004; Lloyd-Still 2001; Oudshoorn 2007; Papas 2007). Four tri-
als did not give an oral calorie supplement with the objective of
increasing calorie intake (Best 2004; Caramia 2003; Grey 2003;
Milla 1996). Three trials were of insufficient duration (less than
one month) (Adde 1997; Kane 1991; Sondel 1987). One trial was
not randomised (Patchell 2001) and a further trial was a quasi-
RCT, but the groups were not comparable at baseline (Steinkamp
2000). One trial did not have a comparator group without an oral
supplement (Lepage 2002) and in one trial the calorie supplement
was not given orally (McKenna 1985).
Risk of bias in included studies
Allocation
In the trial by Hanning and the CALICO trial, generation of the
randomisation sequence was based on a table of random numbers
and so we judged these trials to have a low risk of bias (Hanning
1993; Poustie 2006). In the trial by Kalnins, participants were
segregated by age and sex and the initial participants from each
group were randomly allocated to intervention or control (Kalnins
2005). The paper does not give any details of how this randomi-
sation was undertaken, so we deemed this trial to have an unclear
risk of bias (Kalnins 2005).
Allocation in the Hanning trial and the CALICO trial was con-
cealed using sealed envelopes and we judged these trials to have a
low risk of bias (Hanning 1993; Poustie 2006). The trial byKalnins
was quasi-randomised, initial participants from each group were
randomly allocated to intervention or control, then each subse-
quent participant was allocated a different group from the previ-
ous one (Kalnins 2005). We therefore judged this trial to have a
potential risk of bias.
Blinding
Due to the interventions, blinding of clinicians and participants
was not possible in any of the three included trials, but all three
trials blinded the outcome assessors for some or all outcomes.
In the Hanning trial, investigators performing skeletal and lung
muscle-function tests and anthropometry were unaware of the
participant’s study group (Hanning 1993). In the CALICO trial,
the researcher undertaking the analysis of outcomes was masked
as to the allocation groups (Poustie 2006). These two trials were
deemed to have some risk of bias. In the Kalnins trial apart from
the ’study monitors’ (nurse and dietitian), all other investigators
were blinded (but it was not clear whether all investigators who
assessed the outcomemeasures were blinded) (Kalnins 2005). Due
to this fact the risk of bias for this trial is unclear.
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Incomplete outcome data
In the Hanning trial, an intention-to-treat analysis was not per-
formed (Hanning 1993); 20 participants were randomised but
data from only 16 participants were presented. The paper does
give reasons for the four participants withdrawing (they found the
time demands for testing or the travelling distance to be excessive)
(Hanning 1993). We therefore judged this trial to have a low risk
of bias from incomplete outcome data.
In the Kalnins trial, two participants (one in each group) dropped
out after completing baseline (reasons were feeling unwell and
change of mind) and were not followed up (Kalnins 2005). Two
out of seven participants allocated to the supplement group were
not taking supplements at three months, but were included in the
analysis, which was judged to be intention to treat (Kalnins 2005).
We judged there to be some risk of bias in this trial since although
the withdrawals were described and the analysis was by intention
to treat, the drop outs were not equal across groups.
In the CALICO trial, analysis was by intention to treat (Poustie
2006). It was stated that all 102 children randomised completed
the trial; however there were some data not available for some of
the outcomes. Interim data on two children from the supplement
group (due to parental choice or illness) and on one child from
the standard care group (due to illness) were not collected. We
judged there to be little risk of bias here as the drop outs were
equal across groups and for similar reasons. Furthermore, nine
children failed to return the baseline diet diary and 39 failed to
return the 12-month diet diary (no details given for which group
these children were allocated to), so dietary intake data are based
on the 58 children who completed both diaries. Spirometry data
are available for 70 of the 72 children who were aged over five
years, again no details are given as to which group the two missing
sets of data were from.
Selective reporting
Two trials had an unclear risk of bias as they did not report adverse
events; however it was unclear if this was due to a lack of adverse
events or a failure to report them (Hanning 1993; Kalnins 2005).
Kalnins did not report the change from baseline values for out-
come measures in the original publication, but has since provided
summary statistics for the change from baseline to the authors of
this review (Kalnins 2005). One trial was judged to have a low
risk of bias for selective reporting as all outcomes described in the
’Methods’ section of the full paper are reported in the ’Results’
section (Poustie 2006).
Other potential sources of bias
In the Hanning trial, it was noted that the participants in the
treated group appeared to be in better clinical condition at baseline
than in the control group (Hanning 1993). This could potentially
be a source of bias.
Effects of interventions
See: Summary of findings for the main comparison
It should be noted that the total number of participants included
in this review was 131; 16 from one trial (Hanning 1993), 13
from the second trial (Kalnins 2005) and 102 from the third trial
(Poustie 2006). In theHanning trial, the groupswere not similar at
baseline, therefore we have not included these results. We have at-
tempted, as yet unsuccessfully, to obtain further information from
the authors, in particular the mean change from baseline for all
outcomes relevant to the review and data on the four participants
who dropped out, to enable an intention-to-treat analysis.
The majority of the participants in this review were from the
CALICO trial. Where possible, the outcomes measured at three
and six months from the Kalnins andHanning trials are combined
with the CALICO trial. All the outcomes reported at 12 months
are from the CALICO trial (Poustie 2006).
Primary outcome
1. Change in weight or height or BMI or z score or other
indices of nutrition or growth
a. Change in weight
There was no significant difference between the groups at any time
point (Analysis 1.1); although data from two trials showed a trend
for the supplement group to have greater improvement at three
months, MD 0.32 kg (95% CI -0.09 to 0.72) (Kalnins 2005;
Poustie 2006), and from two trials at six months MD 0.47 kg
(95% CI -0.07 to 1.02) (Hanning 1993; Poustie 2006). However,
this was not apparent from a single trial at 12 months, MD 0.16
kg (95% CI -0.68 to 1.00) (Poustie 2006).
b. Change in weight centile
Data were only available from one trial (Poustie 2006). There was
no significant difference between the groups at three months, MD
1.72 percentile points (95% CI -0.59 to 4.03), at six months, MD
2.12 percentile points (95% CI -0.94 to 5.18) or 12 months, MD
1.83 percentile points (95% CI -1.77 to 5.43) (Analysis 1.2).
c. Change in height
There was no significant difference between the groups at three
months (two trials (Kalnins 2005; Poustie 2006)), MD -0.04 cm
(95% CI -0.36 to 0.29), at six months (one trial (Poustie 2006)),
MD -0.47 cm (95% CI -1.32 to 0.38) or at 12 months (one trial
(Poustie 2006)), MD 0.06 cm (95% CI -0.50 to 0.62) (Analysis
1.3).
12Oral calorie supplements for cystic fibrosis (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
d. Change in height centile
Data were only available from one trial (Poustie 2006). Analy-
sis showed no significant difference between the groups at three
months, MD -0.56 percentile points (95% CI -2.04 to 0.92), at
six months, MD -1.74 percentile points (95% CI -4.40 to 0.92)
or at 12 months, MD -0.65 percentile points (95% CI -3.11 to
1.81) (Analysis 1.4).
e. Weight for height
Data were only available from one trial (Kalnins 2005); at three
months there was no significant difference between the groups,
MD -0.96% (95% CI -5.23 to 3.31) (Analysis 1.5).
f. Change in BMI
Data were only available from one trial (Poustie 2006). There was
no significant difference between the groups at three months, MD
0.14 kg/m² (95% CI -0.08 to 0.36), at six months, MD 0.24 kg/
m² (95% CI -0.06 to 0.54) or at 12 months, MD 0.08 kg/m²
(95% CI -0.28 to 0.44) (Analysis 1.6).
g. Change in BMI centile
Data were only available from one trial (Poustie 2006). There was
no significant difference between the groups at three months, MD
3.28 percentile points (95% CI -0.70 to 7.26), at six months, MD
5.75 percentile points (95% CI 0.22 to 11.28) or at 12 months,
MD 2.99 percentile points (95% CI -2.69 to 8.67) (Analysis 1.7).
Secondary outcomes
1. Anthropometric measures of body composition
a. Change in mid-upper arm circumference
Data were only available from one trial (Poustie 2006). There was
no significant difference between the groups at three months, MD
0.19 cm (95% CI -0.25 to 0.63), at six months, MD 0.22 cm
(95% CI -0.17 to 0.61) or at 12 months, MD 0.21 cm (95% CI
-0.27 to 0.69) (Analysis 1.8).
2.Total calorie intake measured daily or weekly or over
some other time interval
a. Change in total calorie intake
There was no significant difference between the groups at three
months (two trials (Kalnins 2005; Poustie 2006)), MD 115.09
Kcal (95% CI -121.34 to 351.52) (Analysis 1.9). Data at six
months and 12 months were only reported in one trial (Poustie
2006); these data showed that the total calorie intake recorded
in the supplement group was greater; at six months, MD 304.86
Kcal (95% CI 5.62 to 604.10), and at 12 months, MD 265.70
Kcal (95% CI 42.94 to 488.46) (Analysis 1.9).
b. Change in total protein intake
There was no significant difference between the groups at three
months (two trials (Kalnins 2005; Poustie 2006)), MD 2.51 g/day
(95% CI -6.74 to 11.77), at six months (one trial (Poustie 2006)),
MD 8.77 g/day (95% CI -1.24 to 18.78) or at 12 months (one
trial (Poustie 2006)), MD 6.82 g/day (95% CI -2.36 to 16.00)
(Analysis 1.10).
c. Change in total fat intake
There was no significant difference between the groups at three
months (two trials (Kalnins 2005; Poustie 2006)),MD-1.10 g/day
(95%CI 15.05 to 12.85), at six months (one trial (Poustie 2006)),
MD 11.74 g/day (95% CI -2.96 to 6.44) or at 12 months (one
trial (Poustie 2006)), MD 8.85 g/day (95% CI -4.64 to 22.34)
(Analysis 1.11).
3. Calorie intake from food measured daily, weekly or over
some other time interval
No study reported this outcome measure.
4. Calorie intake from OCS measured daily, weekly or over
some other time interval
This outcome was only reported in one trial; at the three-month
time point, mean (SD) calorie intake per day from supplements
was 126.8 (387.7) Kcal in the supplement group (Kalnins 2005).
5. Nutrient intake measured daily, weekly or at some other
time interval
No trial reported this outcome measure.
6. Measures of eating behaviour
No trial reported this outcome.
7. Measures of quality of life
No trial reported this outcome.
8. Adverse effects including diarrhoea, reduced appetite,
abdominal bloating, episodes of distal intestinal obstruction
syndrome and any other adverse effects reported
The CALICO trial investigated gastro-intestinal symptoms with a
questionnaire and reported no significant difference between the
groups (Poustie 2006).
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9. Measures of lung function
a. Change in FEV
(% predicted)
At threemonths, the change in FEV (%predicted) was greater in
the control group (two trials (Kalnins 2005; Poustie 2006)), MD
-7.96% (95% CI -13.52 to -2.40), but there was no significant
difference between groups at sixmonths (one trial (Poustie 2006)),
MD -3.39% (95% CI -9.97 to 3.19) (Poustie 2006), or at 12
months (one trial (Poustie 2006)), MD -1.91% (95% CI -8.57 to
4.75) (Analysis 1.12).
b. Change in FVC (% predicted)
Data were only available from one trial (Poustie 2006). There was
no significant difference between the groups at three months, MD
0.12% (95% CI -9.17 to 9.41), at six months, MD -0.13% (95%
CI -9.07 to 8.81) or at 12 months, MD 5.27% (95% CI -3.67 to
14.21) (Analysis 1.13).
10. Number of deaths or age at death in each group
None of the trials reported any deaths.
11. Activity levels (post-hoc change)
Data were only available from one trial (Poustie 2006). There was
no significant difference between the groups at three months, MD
0.52% in 24 hours (95% CI -3.89 to 4.93), at six months, MD -
1.84% in 24 hours (95% CI -6.38 to 2.70) or at 12 months, MD
-0.08% in 24 hours (95% CI -4.05 to 3.89) (Analysis 1.14).
D I S C U S S I O N
Summary of main results
This Cochrane Review has shown that use of oral protein energy
supplements does not improve nutritional status in people with
cystic fibrosis (CF). It suggests that dietary advice alone is a sat-
isfactory approach to the management of people with CF and
moderate malnutrition. This has implications for the nutritional
management of CF as these products are widely prescribed and are
expensive. We feel that oral protein calorie supplements should
not be regarded as an essential part of the long-term clinical care
of children with CF who are moderately malnourished.
Overall completeness and applicability of
evidence
There are some issues which should be considered when assess-
ing the implications of the review for clinical practice. Firstly, the
result of this review was largely contributed to by the CALICO
study (Poustie 2006). This study was conducted in children, not
adults, who were moderately malnourished and the intervention
given was in the form of oral protein energy supplements, taken as
drinks, over the long term. The children generally had good lung
function (mean forced expiratory volume in one second (FEV )
% predicted was greater than 70%) and did not have severe com-
plications of CF. Therefore one must be cautious in considering
whether the results of this review can be applied to adults with
more severe lung disease or worse nutritional status or both. Addi-
tionally, the short-term use of nutritional supplements as a strat-
egy to treat acute weight loss was not assessed in any other trial
included in this review.
Total energy and macronutrient intake in the included trials were
assessed by information from diaries. The investigators in the
CALICO trial reviewed this carefully and felt that the diary infor-
mation was likely to be an overestimate of the participants’ intake
from supplements, as supplement groups seemed to be consuming
about 18% more than the standard care group relative to their
estimated average requirement for energy intake, but showed no
change in nutritional status. Hence reported intake of food and
other nutrients by participants should be interpreted with caution
in clinical studies.
Quality of the evidence
The quality of the evidence was judged to be moderate for the
change in weight and height and low for the change in total calo-
ries, total fat and total protein intake (this is because results are ap-
plicable only to children between the ages of two and 15 years and
many post-treatment diet diaries were not returned). Evidence for
the rate of adverse events in the treatment groups was extremely
limited and judged to be of very low quality.
Potential biases in the review process
The authors undertook comprehensive searching for this review
so there is unlikely to be any bias due to the non-identification
of relevant trials. However, the lead author of the review was also
an investigator on the largest included study in the review. To
avoid any potential bias from this fact data from that study were
extracted and checked by an independent person at the editorial
base.
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Agreements and disagreements with other
studies or reviews
Despite the findings of this review, guidelines from the USA (CFF
2016) and the UK (UK CF Trust 2010; UK CF Trust 2013)
continue to provide recommendations for their use, although the
statements made are not specific about the clinical situation in
which they should be used. A non-Cochrane systematic review
states, “For children with growth deficits and adults with weight
deficits, the CF Foundation recommends the use of nutritional
supplements (oral and enteral) in addition to usual dietary intake
to improve the rate of weight gain” (Stallings 2008), but does
not reference this Cochrane Review or the CALICO trial (Poustie
2006).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In children with CF who are moderately malnourished the use of
dietary advice and monitoring alone is an appropriate approach
to management. Nutritional supplements may be used but should
not be regarded as an essential part of care.
Implications for research
The place of oral protein energy supplements in the short-term
management of people with CF and acute weight loss should be
assessed in randomised controlled trials. The place of this inter-
vention in the long-termmanagement of adults with CF or people
with advanced lung disease, or both, should also be assessed in
randomised controlled trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Hanning 1993
Methods Random allocation using sealed envelopes.
Parallel design, no intention-to-treat analysis.
Duration: 6 months.
Location: single centre in Canada.
Participants 20 children with CF and mild to moderate lung disease, aged 7 - 15 years
Lung function (FEV % predicted) (mean (SD)): control group 84.2% (26.3); supple-
mented group 101.4% (19.4)
% WFH (mean (SD)); control group 95.6% (12.1); supplement group 92.8% (11.3).
20 randomised (12 males), 16 (10 males) studied.
Interventions Dietary supplements, drink powders, milk shakes, tinned puddings to achieve 25% of
normal energy recommendations in addition to normal diet.
No intervention in control groups.
Outcomes Skeletal muscle strength and power
Pulmonary function* and respiratory muscle strength
Height*, weight* and anthropometric measurements*
Habitual physical activity
Body composition
Dietary energy* and nutrient intake*
Energy* and nutrient* intake from supplements
Laboratory measures of nutritional status (e.g. albumin, amino acids)
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Random allocation using based on a table
of random numbers.
Allocation concealment (selection bias) Low risk Used sealed envelopes.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Investigators performing skeletal and lung
muscle-function tests and anthropometry
were unaware of the participant’s study
group
Incomplete outcome data (attrition bias)
All outcomes
Low risk No ITT analysis.
20 randomised, 16 studied. Four partici-
pants did not complete the trial because
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Hanning 1993 (Continued)
they found the time demands for testing or
the travelling distance to be excessive
Selective reporting (reporting bias) Unclear risk No adverse events reported; not clear if no
events occurred or if not reported
Other bias High risk The treated group appeared to be in better
clinical condition at baseline
Kalnins 2005
Methods Quasi-randomised controlled trial.
Parallel design.
Duration: 3 months.
Location: single centre in Canada.
Participants CF participants aged > 10 years. Age on entry to trial: advice group mean (SD) 16.4
years (6.7); supplement group mean (SD) 19.5 years (11.3).
< 90% ideal WFH or 5% reduction in ideal WFH over 3 months.
Most recent published report states 15 were enrolled but 2 dropped out. Gender split:
3/13 were males.
Although 2 out of 7 in the supplement group did not continue taking supplements, they
were analysed as ITT
Interventions High calorie drink to increase energy intake by 20% of predicted energy needs.
Control group received nutritional counselling to increase energy intake by 20% of
predicted energy needs by eating high calorie foods
Outcomes Z scores for weight* and height*, WFH*
Anthropometric measures*
Pulmonary function*
Energy* and nutrient* intake
Faecal balance studies
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Quasi-randomised controlled trial: partic-
ipants were segregated by age and sex, ini-
tial participants from each group randomly
allocated to intervention or control (paper
does not state how initial randomisation
occurred), then each subsequent partici-
pant was allocated a different group from
the previous one
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Kalnins 2005 (Continued)
Allocation concealment (selection bias) High risk Inadequate, used alternate allocation.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Not possible to blind dietitian or partic-
ipant - it was stated that apart from the
’study monitors’ (nurse and dietitian), all
other investigators were blinded, but it was
not clear whether all investigators who as-
sessed the outcome measures were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 2 participants dropped out, one in each
group after completing baseline (reasons
included feeling unwell and change of
mind) and were not followed up; 2 out of
7 participants allocated to the supplement
group were not taking supplements at 3
months, but were included in the analysis,
which was judged to be ITT
Selective reporting (reporting bias) Unclear risk No adverse events reported; not clear if no
events occurred or if not reported
Did not report the change from baseline
values for outcome measures in the original
publication, but has since provided sum-
mary statistics for the change from baseline
to the authors of this review
Other bias Unclear risk Unable to make clear judgement.
Poustie 2006
Methods Randomised controlled trial.
Parallel design.
Duration: 12 months.
Location: multicentre in UK.
Participants 102 children (54 males) aged 2 - 15 years with CF and at least one of following criteria:
BMI < 25th centile but > 0.4th centile; or no increase in weight over the previous 3
months; or 5% decrease in weight from baseline over a period of < 6 months
Interventions Oral calorie supplements (range of different brands used, but daily amount to increase
usual energy intake by 20%) plus routine dietetic advice compared with dietary advice
alone
Outcomes Change in BMI*
Change in BMI percentile*
Change in weight*
Change in height*
Change in weight percentile*
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Poustie 2006 (Continued)
Change in height percentile*
Mid-upper arm circumference*
Energy* and macro-nutrient* intake
FEV and FVC expressed as % predicted for age, sex and height*
Gastro-intestinal symptoms*
Outcomes measured at 3, 6 and 12 months. All participants were followed up to 12
months
Notes
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Generation of the randomisation sequence
used random number tables
Allocation concealment (selection bias) Low risk Used sealed opaque envelopes.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Not possible to blind clinicians and partic-
ipants, but the researcher undertaking the
analysis of outcomes was masked as to the
allocation groups
Incomplete outcome data (attrition bias)
All outcomes
Low risk Analysis was by ITT. All 102 randomised
children completed the trial. However, un-
able to collect interim data on 2 chil-
dren from the supplement group (owing to
parental choice or illness) and 1 child from
the standard care group (illness)
Nine children failed to return the baseline
diet diary, and 39 failed to return the 12-
month diet diary, so dietary intake data are
based on the 58 children who completed
both baseline and 12 month diaries
Spirometry data available for 70 of the 72
participants aged 5 and above
Selective reporting (reporting bias) Low risk All outcomes described in theMethods sec-
tion of the published paper (including ad-
verse events) reported on
Other bias Low risk Noother potential source of bias identified.
*Outcomes to be included in review
BMI: body mass index
CF: cystic fibrosis
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FEV : forced expiratory volume in 1 second
ITT: intention-to-treat
SD: standard deviation
WFH: weight for height
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abdulhamid 2008 Intervention is zinc supplementation, not an OCS.
Adde 1997 Intervention was only given in hospital and while it does not explicitly state the duration of the intervention
it is highly unlikely to meet our inclusion criteria of at least one month. Furthermore, there is no evidence of
randomisation
Best 2004 OCS not given to increase calorie intake.
Bruzzese 2007 Intervention is a pro-biotic, not an OCS.
Caramia 2003 OCS not given to increase calorie intake.
Ellis 1998 The products used were formula-based infant milks and not OCS
Grey 2003 Supplements used for reasons other than to increase calorie input
Haworth 2004 Intervention is calcium and vitamin D supplements, not an OCS
Kane 1991 OCS taken for less than one month. Both groups received OCS.
Lepage 2002 No comparison with a group not receiving OCS.
Lloyd-Still 2001 Intervention not an OCS.
McKenna 1985 Supplements not given orally.
Milla 1996 OCS not given to increase calorie intake. OCS given for period less than one month
Oudshoorn 2007 Intervention uses micronutrient supplements not OCS.
Papas 2007 Pharmacokinetic trial of different formulations of vitamin E supplementation, not OCS
Patchell 2001 Not a randomised controlled trial.
Sondel 1987 OCS taken for less than one month. Both intervention groups received supplements
Steinkamp 2000 Groups not comparable at the start of the study and quasi-randomised design
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OCS: oral calorie supplements
Characteristics of studies awaiting assessment [ordered by study ID]
MacDonald 2001
Methods Randomised parallel study comparing supplementation with control in CF
Participants People with CF.
Interventions Supplementary feed ’Healthshake’.
Outcomes Growth and biochemistry.
Notes Publication ID: N0045006074.
Title: Evaluation of supplementary feed (Healthshake) in the nutritional management of children with cystic fibrosis.
NRR data provider: Birmingham Children’s Hospital NHS Foundation Trust
CF: cystic fibrosis
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D A T A A N D A N A L Y S E S
Comparison 1. Oral calorie supplements versus no intervention or additional nutritional advice
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Change in weight (kg) 3 Mean Difference (IV, Fixed, 95% CI) Subtotals only
1.1 3 months 2 112 Mean Difference (IV, Fixed, 95% CI) 0.32 [-0.09, 0.72]
1.2 6 months 2 117 Mean Difference (IV, Fixed, 95% CI) 0.47 [-0.07, 1.02]
1.3 12 months 1 102 Mean Difference (IV, Fixed, 95% CI) 0.16 [-0.68, 1.00]
2 Change in weight centile
(percentile points)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
2.1 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.2 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
2.3 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Change in height (cm) 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.1 3 months 2 112 Mean Difference (IV, Fixed, 95% CI) -0.04 [-0.36, 0.29]
3.2 6 months 1 101 Mean Difference (IV, Fixed, 95% CI) -0.47 [-1.32, 0.38]
3.3 12 months 1 102 Mean Difference (IV, Fixed, 95% CI) 0.06 [-0.50, 0.62]
4 Change in height centile
(percentile points)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
4.1 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.2 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
4.3 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Change in weight for height
(percentage)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
5.1 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Change in BMI (kg/m2) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
6.1 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.2 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
6.3 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7 Change in BMI centile
(percentile points)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
7.1 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.2 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
7.3 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8 Change in mid-upper arm
circumference (cm)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
8.1 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.2 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
8.3 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Change in total Kcal/day 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
9.1 3 months 2 58 Mean Difference (IV, Fixed, 95% CI) 115.09 [-121.34,
351.52]
9.2 6 months 1 48 Mean Difference (IV, Fixed, 95% CI) 304.86 [5.62, 604.
10]
9.3 12 months 1 58 Mean Difference (IV, Fixed, 95% CI) 265.70 [42.94, 488.
46]
10 Change in total protein (g)/day 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
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10.1 3 months 2 58 Mean Difference (IV, Fixed, 95% CI) 2.51 [-6.74, 11.77]
10.2 6 months 1 48 Mean Difference (IV, Fixed, 95% CI) 8.77 [-1.24, 18.78]
10.3 12 months 1 58 Mean Difference (IV, Fixed, 95% CI) 6.82 [-2.36, 16.00]
11 Change in total fat (g)/day 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
11.1 3 months 2 58 Mean Difference (IV, Fixed, 95% CI) -1.10 [-15.05, 12.
85]
11.2 6 months 1 48 Mean Difference (IV, Fixed, 95% CI) 11.74 [-2.96, 26.44]
11.3 12 months 1 58 Mean Difference (IV, Fixed, 95% CI) 8.85 [-4.64, 22.34]
12 Change in FEV (% predicted) 2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
12.1 3 months 2 82 Mean Difference (IV, Fixed, 95% CI) -7.96 [-13.52, -2.40]
12.2 6 months 1 70 Mean Difference (IV, Fixed, 95% CI) -3.39 [-9.97, 3.19]
12.3 12 months 1 70 Mean Difference (IV, Fixed, 95% CI) -1.91 [-8.57, 4.75]
13 Change in FVC (% predicted) 1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
13.1 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.2 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
13.3 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Change in activity (% 24
hours)
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
14.1 3 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.2 6 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
14.3 12 months 1 Mean Difference (IV, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional
advice, Outcome 1 Change in weight (kg).
Review: Oral calorie supplements for cystic fibrosis
Comparison: 1 Oral calorie supplements versus no intervention or additional nutritional advice
Outcome: 1 Change in weight (kg)
Study or subgroup Supplements Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months
Kalnins 2005 7 1.46 (2.15) 6 2.15 (2.59) 2.4 % -0.69 [ -3.30, 1.92 ]
Poustie 2006 48 1.11 (1.25) 51 0.77 (0.73) 97.6 % 0.34 [ -0.07, 0.75 ]
Subtotal (95% CI) 55 57 100.0 % 0.32 [ -0.09, 0.72 ]
Heterogeneity: Chi2 = 0.58, df = 1 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 1.54 (P = 0.12)
2 6 months
Hanning 1993 9 2.52 (1.33) 7 1.33 (1.35) 16.8 % 1.19 [ -0.13, 2.51 ]
Poustie 2006 50 2.05 (1.8) 51 1.72 (1.18) 83.2 % 0.33 [ -0.26, 0.92 ]
-4 -2 0 2 4
Favours control Favours supplements
(Continued . . . )
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(. . . Continued)
Study or subgroup Supplements Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Subtotal (95% CI) 59 58 100.0 % 0.47 [ -0.07, 1.02 ]
Heterogeneity: Chi2 = 1.35, df = 1 (P = 0.25); I2 =26%
Test for overall effect: Z = 1.71 (P = 0.087)
3 12 months
Poustie 2006 50 3.13 (2.35) 52 2.97 (1.97) 100.0 % 0.16 [ -0.68, 1.00 ]
Subtotal (95% CI) 50 52 100.0 % 0.16 [ -0.68, 1.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.37 (P = 0.71)
-4 -2 0 2 4
Favours control Favours supplements
Analysis 1.2. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional
advice, Outcome 2 Change in weight centile (percentile points).
Review: Oral calorie supplements for cystic fibrosis
Comparison: 1 Oral calorie supplements versus no intervention or additional nutritional advice
Outcome: 2 Change in weight centile (percentile points)
Study or subgroup Supplements Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months
Poustie 2006 48 2.12 (6.58) 51 0.4 (4.98) 1.72 [ -0.59, 4.03 ]
2 6 months
Poustie 2006 50 2.75 (9.56) 51 0.63 (5.6) 2.12 [ -0.94, 5.18 ]
3 12 months
Poustie 2006 50 0.83 (10.96) 52 -1 (7.14) 1.83 [ -1.77, 5.43 ]
-10 -5 0 5 10
Favours control Favours supplements
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Analysis 1.3. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional
advice, Outcome 3 Change in height (cm).
Review: Oral calorie supplements for cystic fibrosis
Comparison: 1 Oral calorie supplements versus no intervention or additional nutritional advice
Outcome: 3 Change in height (cm)
Study or subgroup Supplements Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months
Kalnins 2005 7 2.17 (2.54) 6 2.55 (2.36) 1.5 % -0.38 [ -3.05, 2.29 ]
Poustie 2006 48 1.65 (0.86) 51 1.68 (0.8) 98.5 % -0.03 [ -0.36, 0.30 ]
Subtotal (95% CI) 55 57 100.0 % -0.04 [ -0.36, 0.29 ]
Heterogeneity: Chi2 = 0.07, df = 1 (P = 0.80); I2 =0.0%
Test for overall effect: Z = 0.21 (P = 0.83)
2 6 months
Poustie 2006 50 3.09 (1.03) 51 3.56 (2.92) 100.0 % -0.47 [ -1.32, 0.38 ]
Subtotal (95% CI) 50 51 100.0 % -0.47 [ -1.32, 0.38 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.08 (P = 0.28)
3 12 months
Poustie 2006 50 5.91 (0.85) 52 5.85 (1.85) 100.0 % 0.06 [ -0.50, 0.62 ]
Subtotal (95% CI) 50 52 100.0 % 0.06 [ -0.50, 0.62 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
-4 -2 0 2 4
Favours control Favours supplements
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Analysis 1.4. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional
advice, Outcome 4 Change in height centile (percentile points).
Review: Oral calorie supplements for cystic fibrosis
Comparison: 1 Oral calorie supplements versus no intervention or additional nutritional advice
Outcome: 4 Change in height centile (percentile points)
Study or subgroup Supplements Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months
Poustie 2006 48 0.57 (3.69) 51 1.13 (3.81) -0.56 [ -2.04, 0.92 ]
2 6 months
Poustie 2006 50 0.24 (0.27) 51 1.98 (9.7) -1.74 [ -4.40, 0.92 ]
3 12 months
Poustie 2006 50 0.53 (6.94) 52 1.18 (5.62) -0.65 [ -3.11, 1.81 ]
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Analysis 1.5. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional
advice, Outcome 5 Change in weight for height (percentage).
Review: Oral calorie supplements for cystic fibrosis
Comparison: 1 Oral calorie supplements versus no intervention or additional nutritional advice
Outcome: 5 Change in weight for height (percentage)
Study or subgroup Supplements Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months
Kalnins 2005 7 0.71 (4.5) 6 1.67 (3.33) -0.96 [ -5.23, 3.31 ]
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Analysis 1.6. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional
advice, Outcome 6 Change in BMI (kg/m2).
Review: Oral calorie supplements for cystic fibrosis
Comparison: 1 Oral calorie supplements versus no intervention or additional nutritional advice
Outcome: 6 Change in BMI (kg/m2)
Study or subgroup Supplements Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months
Poustie 2006 48 0.19 (0.65) 51 0.05 (0.41) 0.14 [ -0.08, 0.36 ]
2 6 months
Poustie 2006 50 0.39 (0.87) 51 0.15 (0.67) 0.24 [ -0.06, 0.54 ]
3 12 months
Poustie 2006 50 0.32 (1.03) 52 0.24 (0.78) 0.08 [ -0.28, 0.44 ]
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Analysis 1.7. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional
advice, Outcome 7 Change in BMI centile (percentile points).
Review: Oral calorie supplements for cystic fibrosis
Comparison: 1 Oral calorie supplements versus no intervention or additional nutritional advice
Outcome: 7 Change in BMI centile (percentile points)
Study or subgroup Supplements Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months
Poustie 2006 48 2.72 (11.42) 51 -0.56 (8.47) 3.28 [ -0.70, 7.26 ]
2 6 months
Poustie 2006 50 4.46 (15.5) 51 -1.29 (12.66) 5.75 [ 0.22, 11.28 ]
3 12 months
Poustie 2006 50 0.67 (18.2) 52 -2.32 (9.63) 2.99 [ -2.69, 8.67 ]
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Analysis 1.8. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional
advice, Outcome 8 Change in mid-upper arm circumference (cm).
Review: Oral calorie supplements for cystic fibrosis
Comparison: 1 Oral calorie supplements versus no intervention or additional nutritional advice
Outcome: 8 Change in mid-upper arm circumference (cm)
Study or subgroup Supplements Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months
Poustie 2006 48 0.44 (1.41) 51 0.25 (0.64) 0.19 [ -0.25, 0.63 ]
2 6 months
Poustie 2006 50 0.57 (1.24) 51 0.35 (0.65) 0.22 [ -0.17, 0.61 ]
3 12 months
Poustie 2006 50 0.68 (1.44) 52 0.47 (0.95) 0.21 [ -0.27, 0.69 ]
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Analysis 1.9. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional
advice, Outcome 9 Change in total Kcal/day.
Review: Oral calorie supplements for cystic fibrosis
Comparison: 1 Oral calorie supplements versus no intervention or additional nutritional advice
Outcome: 9 Change in total Kcal/day
Study or subgroup Supplements Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months
Kalnins 2005 7 384.6 (1094.5) 6 -43 (912.7) 4.7 % 427.60 [ -663.61, 1518.81 ]
Poustie 2006 21 290.24 (409.33) 24 190.54 (418.27) 95.3 % 99.70 [ -142.48, 341.88 ]
Subtotal (95% CI) 28 30 100.0 % 115.09 [ -121.34, 351.52 ]
Heterogeneity: Chi2 = 0.33, df = 1 (P = 0.57); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
2 6 months
Poustie 2006 27 365.19 (585.72) 21 60.33 (471.88) 100.0 % 304.86 [ 5.62, 604.10 ]
Subtotal (95% CI) 27 21 100.0 % 304.86 [ 5.62, 604.10 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.00 (P = 0.046)
3 12 months
Poustie 2006 27 405.22 (371.2) 31 139.52 (492.18) 100.0 % 265.70 [ 42.94, 488.46 ]
Subtotal (95% CI) 27 31 100.0 % 265.70 [ 42.94, 488.46 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.34 (P = 0.019)
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Analysis 1.10. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional
advice, Outcome 10 Change in total protein (g)/day.
Review: Oral calorie supplements for cystic fibrosis
Comparison: 1 Oral calorie supplements versus no intervention or additional nutritional advice
Outcome: 10 Change in total protein (g)/day
Study or subgroup Supplements Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months
Kalnins 2005 7 13 (45.9) 6 10.8 (27.6) 5.2 % 2.20 [ -38.34, 42.74 ]
Poustie 2006 21 10.4 (16.51) 24 7.87 (15.91) 94.8 % 2.53 [ -6.98, 12.04 ]
Subtotal (95% CI) 28 30 100.0 % 2.51 [ -6.74, 11.77 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.99); I2 =0.0%
Test for overall effect: Z = 0.53 (P = 0.59)
2 6 months
Poustie 2006 27 13.98 (20.32) 21 5.21 (15.07) 100.0 % 8.77 [ -1.24, 18.78 ]
Subtotal (95% CI) 27 21 100.0 % 8.77 [ -1.24, 18.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.72 (P = 0.086)
3 12 months
Poustie 2006 27 12.57 (16.41) 31 5.75 (19.27) 100.0 % 6.82 [ -2.36, 16.00 ]
Subtotal (95% CI) 27 31 100.0 % 6.82 [ -2.36, 16.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.15)
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Analysis 1.11. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional
advice, Outcome 11 Change in total fat (g)/day.
Review: Oral calorie supplements for cystic fibrosis
Comparison: 1 Oral calorie supplements versus no intervention or additional nutritional advice
Outcome: 11 Change in total fat (g)/day
Study or subgroup Supplements Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months
Kalnins 2005 7 11.7 (54.6) 6 -26.9 (60) 4.9 % 38.60 [ -24.18, 101.38 ]
Poustie 2006 21 11.93 (23.9) 24 15.09 (25.03) 95.1 % -3.16 [ -17.47, 11.15 ]
Subtotal (95% CI) 28 30 100.0 % -1.10 [ -15.05, 12.85 ]
Heterogeneity: Chi2 = 1.62, df = 1 (P = 0.20); I2 =38%
Test for overall effect: Z = 0.15 (P = 0.88)
2 6 months
Poustie 2006 27 14.06 (28.27) 21 2.32 (23.66) 100.0 % 11.74 [ -2.96, 26.44 ]
Subtotal (95% CI) 27 21 100.0 % 11.74 [ -2.96, 26.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.57 (P = 0.12)
3 12 months
Poustie 2006 27 21.08 (24.56) 31 12.23 (27.86) 100.0 % 8.85 [ -4.64, 22.34 ]
Subtotal (95% CI) 27 31 100.0 % 8.85 [ -4.64, 22.34 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
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Analysis 1.12. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional
advice, Outcome 12 Change in FEV (% predicted).
Review: Oral calorie supplements for cystic fibrosis
Comparison: 1 Oral calorie supplements versus no intervention or additional nutritional advice
Outcome: 12 Change in FEV (% predicted)
Study or subgroup Supplements Control
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months
Kalnins 2005 7 -6.6 (14.6) 6 1.6 (13.3) 13.4 % -8.20 [ -23.37, 6.97 ]
Poustie 2006 31 -2.55 (12.28) 38 5.37 (12.97) 86.6 % -7.92 [ -13.89, -1.95 ]
Subtotal (95% CI) 38 44 100.0 % -7.96 [ -13.52, -2.40 ]
Heterogeneity: Chi2 = 0.00, df = 1 (P = 0.97); I2 =0.0%
Test for overall effect: Z = 2.81 (P = 0.0050)
2 6 months
Poustie 2006 32 -1.78 (11.51) 38 1.61 (16.45) 100.0 % -3.39 [ -9.97, 3.19 ]
Subtotal (95% CI) 32 38 100.0 % -3.39 [ -9.97, 3.19 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.01 (P = 0.31)
3 12 months
Poustie 2006 32 -3.41 (13.5) 38 -1.5 (14.89) 100.0 % -1.91 [ -8.57, 4.75 ]
Subtotal (95% CI) 32 38 100.0 % -1.91 [ -8.57, 4.75 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.56 (P = 0.57)
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Analysis 1.13. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional
advice, Outcome 13 Change in FVC (% predicted).
Review: Oral calorie supplements for cystic fibrosis
Comparison: 1 Oral calorie supplements versus no intervention or additional nutritional advice
Outcome: 13 Change in FVC (% predicted)
Study or subgroup Supplements Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months
Poustie 2006 30 1.47 (13.98) 37 1.35 (24.31) 0.12 [ -9.17, 9.41 ]
2 6 months
Poustie 2006 31 -3 (17.71) 38 -2.87 (20.16) -0.13 [ -9.07, 8.81 ]
3 12 months
Poustie 2006 31 0.06 (17.82) 38 -5.21 (20.02) 5.27 [ -3.67, 14.21 ]
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Analysis 1.14. Comparison 1 Oral calorie supplements versus no intervention or additional nutritional
advice, Outcome 14 Change in activity (% 24 hours).
Review: Oral calorie supplements for cystic fibrosis
Comparison: 1 Oral calorie supplements versus no intervention or additional nutritional advice
Outcome: 14 Change in activity (% 24 hours)
Study or subgroup Supplements Control
Mean
Difference
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 3 months
Poustie 2006 47 -0.34 (9.86) 51 -0.86 (12.36) 0.52 [ -3.89, 4.93 ]
2 6 months
Poustie 2006 50 -3.43 (10.62) 51 -1.59 (12.6) -1.84 [ -6.38, 2.70 ]
3 12 months
Poustie 2006 50 -4.97 (9.77) 52 -4.89 (10.7) -0.08 [ -4.05, 3.89 ]
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WH A T ’ S N E W
Last assessed as up-to-date: 26 April 2017.
Date Event Description
26 April 2017 New search has been performed A search of the Cochrane Cystic Fibrosis and Genetic
Disorders Review Group’s Cystic Fibrosis Trials Register
identified a single new reference which was potentially
eligible for inclusion in this review and which has been
excluded (Adde 1997).
A summary of findings table has been added to the review.
26 April 2017 New citation required but conclusions have not changed As no new data have been added at this update, our con-
clusions remain the same
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H I S T O R Y
Protocol first published: Issue 1, 1997
Review first published: Issue 1, 1998
Date Event Description
27 October 2014 New citation required but conclusions have not
changed
A new author has joined the review team (Oli Rayner)
after a previous author has stepped down from the
review
As no new trials have been included in this updated
review, our conclusions remain the same
27 October 2014 New search has been performed A search of the Cystic Fibrosis & Genetic Disorders
Review Group’s Cystic Fibrosis Trials Register did not
identify any new studies for possible inclusion in this
review
The Plain Language Summary has been updated to
reflect new guidance on style
17 October 2012 Amended Contact details updated.
4 September 2012 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register
did not identify any new references eligible for inclu-
sion in this review
4 September 2012 New citation required but conclusions have not
changed
No new references have been added to the review at
this update, therefore the conclusions of this review
remain the same
15 September 2010 New search has been performed A search of the Group’s Cystic Fibrosis Trials Register
did not identify any new references which were poten-
tially eligible for inclusion in this review
12 August 2009 Amended Contact details updated.
20 August 2008 New search has been performed A search of the Group’s Cystic Fibrosis Trials Regis-
ter identified two new references. One of these was
an additional reference to an already excluded study
(Abdulhamid 2008); the other reference was excluded
as the intervention was not an oral calorie supplement
(Bruzzese 2007).
19 August 2008 Amended Converted to new review format.
13 November 2007 New search has been performed The search identified twonew references both ofwhich
have been added to the list of excluded studies (Oud-
shoorn 2007; Papas 2007)
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(Continued)
13 November 2007 Amended The Plain Language Summary has been re-drafted in
light of the latest guidance from The Cochrane Col-
laboration
15 November 2006 Amended A post hoc change has been made to the list of sec-
ondary outcomes and ’Activity levels’ has now been
added
15 November 2006 New search has been performed The search identified ten new references to five trials.
One reference was to an already included trial (Kalnins
2005). A further trial has now been included in the
review (Poustie 2006). The other three trials have been
added to ’Excluded studies’ (Abdulhamid 2005; Ha-
worth 2004; Lloyd-Still 2001)
15 November 2006 New citation required and conclusions have changed Substantive amendment
18 August 2004 New search has been performed The search identified three new references. One of
these was an additional reference to a study already
excluded (Grey 2003). The other references were to
two studies, both of which were excluded (Best 2004;
Caramia 2003)
20 August 2003 New search has been performed Three references have been added to the ’Excluded
studies’ section (McKenna 1985; Lands 2000; Lepage
2002).
One reference has been added to the ’Ongoing studies’
section (CALICO trial 2003)
11 July 2002 New search has been performed A search of the Group’s trials register found no new
trials eligible for inclusion in this review
C O N T R I B U T I O N S O F A U T H O R S
Rosalind Smyth and Sarah Walters wrote the protocol and independently assessed studies for inclusion in this review. Rosalind Smyth
extracted the data and wrote the remainder of the text. Rosalind Smyth wrote the updates of this review with comments from Sarah
Walters (up to 2012) and from Oli Rayner (from 2014 onwards).
Rosalind Smyth acts as guarantor of this review.
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Professor Rosalind Smyth was principle investigator in the CALICO trial which is included in this review.
Oli Rayner acts as a consultant to the UK Cystic Fibrosis Trust, a charitable organisation which supports basic and clinical research in
cystic fibrosis. He has carried out work on this review on apro bono basis and it is entirely unrelated to any work with the UK Cystic
Fibrosis Trust. The UK Cystic Fibrosis Trust has no financial interest in the outcome of this review and nor does he.
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute for Health Research, UK.
This systematic review was supported by the National Institute for Health Research, via Cochrane Infrastructure funding to the
Cochrane Cystic Fibrosis and Genetic Disorders Group.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
In November 2006, a post hoc change was made to the list of secondary outcomes and ’Activity levels’ was added.
N O T E S
Please refer to the following Cochrane Review, which assesses the effectiveness of this intervention for children with chronic disease:
Francis DK, Smith J, Saljuqi T,Watling RM.Oral protein calorie supplementation for children with chronic disease. Cochrane Database
of Systematic Reviews 2015, Issue 5. Art. No.: CD001914. DOI: 10.1002/14651858.CD001914.pub2.
I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Dietary Supplements [adverse effects]; ∗Energy Intake; Administration, Oral; Child Nutrition Disorders [∗diet therapy; etiology];
Cystic Fibrosis [∗complications]; Randomized Controlled Trials as Topic
MeSH check words
Adult; Child; Humans
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